

**SYSTEMATIC REVIEW LITERATURE ON THE EFFECTIVENESS OF
THE MEDICINAL SUBSTANCES FOR TARGETED TREATMENT OF
THE RENAL CELL CANCER**

Rajabova Nargiza Xalimovna*; Eshmurodova Feruza Urol qizi**

* Doctoral Student,
Department of Pharmaceutical Organization of the Tashkent Pharmaceutical Institute,
Tashkent, UZBEKISTAN
Email id: nargiza-rh@mail.ru

**Assistant Teacher,
Department of Pharmaceutical Organization of the Tashkent Pharmaceutical Institute,
Tashkent, UZBEKISTAN
Email id: eshmurodovaferuza_269@gmail.com

DOI: 10.5958/2249-7137.2023.00029.0

ABSTRACT

Nowadays, malignant tumors are the second leading cause of death all over the world. Among malignant tumors of the kidney, renal cell cancer accounts for 90%. According to statistic information, stage 2 and 3 of the kidney cancer is more common among patients with this disease. Every year, 403.3 thousand new cases of kidney cancer are revealed in the world and this index is 2-3% of all epithelial malignant tumors.

KEYWORDS: *Arterial Hypertension, Systematic Analyzing The Clinical Literature, Medicinal Substances.*

LITERATURE:

1. L. V. Mirilenko, A. V. Poluyanchik "Predicting the survival of patients with stage IV kidney cancer". *Oncourology* 2019;(1):30-40. <https://cyberleninka.ru/article/n/prognozirovaniye-vyzhivaemosti-patsientov-s-iv-stadiye-raka-pochki>
 2. Aksel E.M., Matveev V.B. "Statistics of malignant neoplasms of the urinary and male genital organs in Russia and the countries of the former USSR". *Oncourology* 2019; 15 (2): 15 – 24. <https://oncourology.abvpress.ru/oncur/article/view/925/843>
 3. B. Ljungberg(1), Clinical Guidelines for Renal Cell Carcinoma <https://ikcc.org/wp-content/uploads/2019/08/EAU-RCC-Guidelines-2018-Russian.pdf>
 4. *Oncourology. Pharmacotherapy without errors / Ed. I. G. Rusakova, V. I. Borisova. — M.: E-noto, 2014. — 544 p. - ISBN 978-5-906023-07-0.*
 5. Rajabova N.H., Suyunov N.D. Epidemiology of cancer in the Republic of Uzbekistan // Today's state of the pharmaceutical industry: problems and prospects" International scientific and practical conference collection. - 2020. p. 120-121.
 6. Lesley-Ann Miller,(1) Patterns of Care in Patients with Metastatic Renal Cell Carcinoma Among a U.S. Payer Population with Commercial or Medicare Advantage Membership., *J Manag Care Spec Pharm* 2016 Mar;22(3):219-26.
-

<https://pubmed.ncbi.nlm.nih.gov/27003551/>

7. Sergio Bracarda,(1) Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial. 1558-7673/^a 2019 <https://doi.org/10.1016/j.clgc.2019.03.017>.
8. Satoshi Tamada,(1) Second-line treatment after sunitinib therapy in patients with renal cell carcinoma: a comparison of axitinib and mammalian target of rapamycin inhibitors. Department of Urology, Osaka City University Graduate School of Medicine, Abeno-ku, Osaka 545–8585, Japan Correspondence to: Satoshi Tamada,
9. Hideaki Miyake,(1) Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in Japan. Elsevier Inc. All rights reserved. <http://dx.doi.org/10.1016/j.clgc.2016.06.019>.
10. Rajabova N.H., Suyunov N.D. Analysis of antitumor drugs registered in the Republic of Uzbekistan // Farmatsevtika journal - Tashkent, Uzbekistan, issue 4, - 2020. p. 3-10.
11. Suyunov, N. D., Razhabova, N. Kh., Ruziev, K. R., Narzikulova, K. Sh. (2019). Medicines used in diseases characterized by high blood pressure and their pricing. Pharmaceutical Journal, 1(3), 4-12.
12. Suyunov, N. D., Rajabova, N. X. (2020). Analysis of anticancer drugs registered in the Republic of Uzbekistan. Farmatsevtichesky journal, 1(4), 3-10.
13. Suyunov, N. D., Rajabova, N. X. (2021). Analysis of the range of drugs used in the treatment of lung cancer. Farmatsevtichesky journal, 1(4), 5-17.
14. Suyunov, N. D., Rajabova, N. X. (2022). Retrospective analysis of medical records of patients with lung cancer. Farmatsevtichesky journal, 1(6), 21-30.
15. Suyunov, N. D., & Rajabova, N. X. (2023). Performance indicators of the medicines used in squamous cell lung cancer. Farmaciya (Pharmacy), 72(1), 36-48.